Therapeutic activity of an anti-idiotypic antibody-derived killer peptide against influenza a virus experimental infection

Giorgio Conti, Walter Magliani, Stefania Conti, Lucia Nencioni, Rossella Sgarbanti, Anna Teresa Palamara, Luciano Polonelli

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The in vitro and in vivo activities of a killer decapeptide (KP) against influenza A virus is described, and the mechanisms of action are suggested. KP represents the functional internal image of a yeast killer toxin that proved to exert antimicrobial and anti-human immunodeficiency virus type 1 (HIV-1) activities. Treatment with KP demonstrated a significant inhibitory activity on the replication of two strains of influenza A virus in different cell lines, as evaluated by hemagglutination, hemadsorption, and plaque assays. The complete inhibition of virus particle production and a marked reduction of the synthesis of viral proteins (membrane protein and hemagglutinin, in particular) were observed at a KP concentration of 4 μg/ml. Moreover, KP administered intraperitoneally at a dose of 100 μg/mice once a day for 10 days to influenza A/NWS/33 (H1N1) virus-infected mice improved the survival of the animals by 40% and significantly decreased the viral titers in their lungs. Overall, KP appears to be the first anti-idiotypic antibody-derived peptide that displays inhibitory activity and that has a potential therapeutic effect against pathogenic microorganisms, HIV-1, and influenza A virus by different mechanisms of action.

Original languageEnglish
Pages (from-to)4331-4337
Number of pages7
JournalAntimicrobial Agents and Chemotherapy
Volume52
Issue number12
DOIs
Publication statusPublished - Dec 2008

Fingerprint

Influenza A virus
Virus Diseases
Orthomyxoviridae
Anti-Idiotypic Antibodies
Peptides
Yeast Killer Factor
HIV-1
Hemadsorption
H1N1 Subtype Influenza A Virus
Hemagglutination
Hemagglutinins
Viral Proteins
Therapeutic Uses
Virion
Human Influenza
Membrane Proteins
Therapeutics
Cell Line
Lung

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)
  • Pharmacology

Cite this

Therapeutic activity of an anti-idiotypic antibody-derived killer peptide against influenza a virus experimental infection. / Conti, Giorgio; Magliani, Walter; Conti, Stefania; Nencioni, Lucia; Sgarbanti, Rossella; Palamara, Anna Teresa; Polonelli, Luciano.

In: Antimicrobial Agents and Chemotherapy, Vol. 52, No. 12, 12.2008, p. 4331-4337.

Research output: Contribution to journalArticle

Conti, Giorgio ; Magliani, Walter ; Conti, Stefania ; Nencioni, Lucia ; Sgarbanti, Rossella ; Palamara, Anna Teresa ; Polonelli, Luciano. / Therapeutic activity of an anti-idiotypic antibody-derived killer peptide against influenza a virus experimental infection. In: Antimicrobial Agents and Chemotherapy. 2008 ; Vol. 52, No. 12. pp. 4331-4337.
@article{97f593144e8c4a5d9212ebeab0a24495,
title = "Therapeutic activity of an anti-idiotypic antibody-derived killer peptide against influenza a virus experimental infection",
abstract = "The in vitro and in vivo activities of a killer decapeptide (KP) against influenza A virus is described, and the mechanisms of action are suggested. KP represents the functional internal image of a yeast killer toxin that proved to exert antimicrobial and anti-human immunodeficiency virus type 1 (HIV-1) activities. Treatment with KP demonstrated a significant inhibitory activity on the replication of two strains of influenza A virus in different cell lines, as evaluated by hemagglutination, hemadsorption, and plaque assays. The complete inhibition of virus particle production and a marked reduction of the synthesis of viral proteins (membrane protein and hemagglutinin, in particular) were observed at a KP concentration of 4 μg/ml. Moreover, KP administered intraperitoneally at a dose of 100 μg/mice once a day for 10 days to influenza A/NWS/33 (H1N1) virus-infected mice improved the survival of the animals by 40{\%} and significantly decreased the viral titers in their lungs. Overall, KP appears to be the first anti-idiotypic antibody-derived peptide that displays inhibitory activity and that has a potential therapeutic effect against pathogenic microorganisms, HIV-1, and influenza A virus by different mechanisms of action.",
author = "Giorgio Conti and Walter Magliani and Stefania Conti and Lucia Nencioni and Rossella Sgarbanti and Palamara, {Anna Teresa} and Luciano Polonelli",
year = "2008",
month = "12",
doi = "10.1128/AAC.00506-08",
language = "English",
volume = "52",
pages = "4331--4337",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "12",

}

TY - JOUR

T1 - Therapeutic activity of an anti-idiotypic antibody-derived killer peptide against influenza a virus experimental infection

AU - Conti, Giorgio

AU - Magliani, Walter

AU - Conti, Stefania

AU - Nencioni, Lucia

AU - Sgarbanti, Rossella

AU - Palamara, Anna Teresa

AU - Polonelli, Luciano

PY - 2008/12

Y1 - 2008/12

N2 - The in vitro and in vivo activities of a killer decapeptide (KP) against influenza A virus is described, and the mechanisms of action are suggested. KP represents the functional internal image of a yeast killer toxin that proved to exert antimicrobial and anti-human immunodeficiency virus type 1 (HIV-1) activities. Treatment with KP demonstrated a significant inhibitory activity on the replication of two strains of influenza A virus in different cell lines, as evaluated by hemagglutination, hemadsorption, and plaque assays. The complete inhibition of virus particle production and a marked reduction of the synthesis of viral proteins (membrane protein and hemagglutinin, in particular) were observed at a KP concentration of 4 μg/ml. Moreover, KP administered intraperitoneally at a dose of 100 μg/mice once a day for 10 days to influenza A/NWS/33 (H1N1) virus-infected mice improved the survival of the animals by 40% and significantly decreased the viral titers in their lungs. Overall, KP appears to be the first anti-idiotypic antibody-derived peptide that displays inhibitory activity and that has a potential therapeutic effect against pathogenic microorganisms, HIV-1, and influenza A virus by different mechanisms of action.

AB - The in vitro and in vivo activities of a killer decapeptide (KP) against influenza A virus is described, and the mechanisms of action are suggested. KP represents the functional internal image of a yeast killer toxin that proved to exert antimicrobial and anti-human immunodeficiency virus type 1 (HIV-1) activities. Treatment with KP demonstrated a significant inhibitory activity on the replication of two strains of influenza A virus in different cell lines, as evaluated by hemagglutination, hemadsorption, and plaque assays. The complete inhibition of virus particle production and a marked reduction of the synthesis of viral proteins (membrane protein and hemagglutinin, in particular) were observed at a KP concentration of 4 μg/ml. Moreover, KP administered intraperitoneally at a dose of 100 μg/mice once a day for 10 days to influenza A/NWS/33 (H1N1) virus-infected mice improved the survival of the animals by 40% and significantly decreased the viral titers in their lungs. Overall, KP appears to be the first anti-idiotypic antibody-derived peptide that displays inhibitory activity and that has a potential therapeutic effect against pathogenic microorganisms, HIV-1, and influenza A virus by different mechanisms of action.

UR - http://www.scopus.com/inward/record.url?scp=57049111193&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57049111193&partnerID=8YFLogxK

U2 - 10.1128/AAC.00506-08

DO - 10.1128/AAC.00506-08

M3 - Article

C2 - 18824612

AN - SCOPUS:57049111193

VL - 52

SP - 4331

EP - 4337

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 12

ER -